Medindia LOGIN REGISTER
Medindia
Advertisement

Semafore to Present at BIO CEO & Investor Conference

Saturday, February 9, 2008 General News
Advertisement
INDIANAPOLIS, Feb. 8 Semafore Pharmaceuticals Inc. todayannounced that Edward L. Jacobs, president and chief executive officer, andUllrich Schwertschlag, M.D., Ph.D., chief medical officer, will present anupdate of the company's product development programs at 2:45 p.m. EST onWednesday, Feb. 13, 2008, at the BIO CEO & Investor Conference in New YorkCity.
Advertisement

The update will include information about Semafore's lead productcandidate, SF1126, a targeted PI3 kinase inhibitor currently in Phase 1clinical trials in solid tumors and multiple myeloma. The presentation willalso include a review of the company's pipeline advancements and businessdevelopment initiatives.
Advertisement

About SF1126

SF1126 is a small molecule conjugate containing a pan-PI3K inhibitor thatselectively inhibits all PI3K class IA isoforms and other key members of thePI3K superfamily, including DNA-PK and mTOR. A major factor in tumorresistance to approved chemotherapy agents is thought to be the activation ofthe PI3K/PTEN pathway. As a result, it is thought that inhibiting thispathway, via SF1126, could cause the resetting of sensitivity to approvedagents and exhibit synergistic anticancer effects.

About Semafore

Semafore is a clinical stage drug discovery and development companyfocused on small molecule modulators of the PI3 kinase and PTEN cell signalingpathway, a promising target pathway for multiple disorders, including thecompany's focus - cancer. Semafore is one of the first biopharmaceuticalcompanies to focus on both PI3K and PTEN and has successfully discovered andis developing a portfolio of drug candidates addressing these targets. Formore information see the company's Web site at www.SemaforePharma.com.Contacts: Corporate Media Semafore Pharmaceuticals Inc. Russo Partners LLC Bob Marshall or Ed Jacobs David Schull or Timothy Engel (480) 278-8200 (212) 845-4271

SOURCE Semafore Pharmaceuticals Inc.
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close